1. Home
  2. LIXT vs INUV Comparison

LIXT vs INUV Comparison

Compare LIXT & INUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

N/A

Current Price

$3.56

Market Cap

26.5M

Sector

Health Care

ML Signal

N/A

Logo Inuvo Inc.

INUV

Inuvo Inc.

HOLD

Current Price

$1.90

Market Cap

28.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIXT
INUV
Founded
2005
N/A
Country
United States
United States
Employees
3
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
28.3M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
LIXT
INUV
Price
$3.56
$1.90
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.00
AVG Volume (30 Days)
37.1K
205.6K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.00
EPS
N/A
N/A
Revenue
N/A
$86,209,305.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.88
52 Week Low
$0.64
$0.36
52 Week High
$6.09
$6.27

Technical Indicators

Market Signals
Indicator
LIXT
INUV
Relative Strength Index (RSI) 58.16 41.34
Support Level $2.50 $1.82
Resistance Level $4.45 $1.99
Average True Range (ATR) 0.28 0.13
MACD 0.06 0.01
Stochastic Oscillator 62.24 24.32

Price Performance

Historical Comparison
LIXT
INUV

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About INUV Inuvo Inc.

Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.

Share on Social Networks: